Zara Shahzad

Ms. Zara Shahzad

Lahore Medical and Dental College, Lahore, Punjab, Pakistan
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2022 in Cells
Verified
Journal Article
Open access
PDF file
Muhammad Saad ShaikhMuhammad Saad Shaikh
Muhammad Saad Shaikh
ZSZara Shahzad
Zara Shahzad
ETEsraa Abdulgader Tash
Esraa Abdulgader Tash
OJOmer Sefvan Janjua
Omer Sefvan Janjua
MKMuhammad Ikram Khan
Muhammad Ikram Khan
Muhammad Sohail ZafarMuhammad Sohail Zafar
Muhammad Sohail Zafar
Periodontal disease can cause irreversible damage to tooth-supporting tissues such as the root cementum, periodontal ligament, and alveolar bone, eventually leading to tooth loss. While standard periodontal treatments are usually helpful in reducing disease progression, they cannot repair or replace lost periodontal tissue. Periodontal regeneration has been demonstrated to be beneficial in treating intraosseous and furcation defects to varied degrees. Cell-based treatment for periodontal regeneration will become more efficient and predictable as tissue engineering and progenitor cell biology advance, surpassing the limitations of present therapeutic techniques. Stem cells are undifferentiated cells with the ability to self-renew and differentiate into several cell types when stimulated. Mesenchymal stem cells (MSCs) have been tested for periodontal regeneration in vitro and in humans, with promising results. Human umbilical cord mesenchymal stem cells (UC-MSCs) possess a great regenerative and therapeutic potential. Their added benefits comprise ease of collection, endless source of stem cells, less immunorejection, and affordability. Further, their collection does not include the concerns associated with human embryonic stem cells. The purpose of this review is to address the most recent findings about periodontal regenerative mechanisms, different stem cells accessible for periodontal regeneration, and UC-MSCs and their involvement in periodontal regeneration.

19 April 2022 in Journal of the Pakistan Medical Association
Verified
Journal Article
Open access
PDF file
ZMZuha Majid
Zuha Majid
ZSZara Shahzad
Zara Shahzad
MNMuhammad Umar Nasir
Muhammad Umar Nasir
No abstract needed for letter to the editor.

6 June 2024
Verified
Preprint
Open access
PDF file
SKSaeed Khan
Saeed Khan
LFLaveeza Fatima
Laveeza Fatima
KSKhurram Shahzad
Khurram Shahzad
ZSZara Shahzad
Zara Shahzad
ARAli Raza
Ali Raza
Keywords: Eosinophilic granulomatosis with polyangiitis (EGPA); Churg-Strauss Syndrome (CSS); Neuropathy; Vasculitis; ANCA-associated vasculitis; Immunosuppressant therapy

22 September 2026 in American Journal of Therapeutics
Verified
Journal Article
Closed access
ARAhmed Raza
Ahmed Raza
FFFaiza Fatima
Faiza Fatima
KKKalpina Kumar
Kalpina Kumar
MUMuhammad S. Ullah
Muhammad S. Ullah
ZSZara Shahzad
Zara Shahzad
MNMudasar Nisar
Mudasar Nisar
Was not provided for this article.

13 August 2026 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
FFFaiza Fatima
Faiza Fatima
AMAeliya Mirza
Aeliya Mirza
MBMuhammad Imaz Bhatti
Muhammad Imaz Bhatti
FHFatima Hussain
Fatima Hussain
ZSZara Shahzad
Zara Shahzad
Objectives: Pirtobrutinib, a noncovalent Bruton tyrosine kinase inhibitor, was developed to overcome resistance mutations that limit covalent BTK inhibitors and to offer improved tolerability. Three phase III randomized trials (BRUIN CLL-321, CLL-313, and CLL-314) have evaluated pirtobrutinib against distinct comparators in different chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) populations, but no pooled evidence exists, as of now. Methods: Following PRISMA 2020 guidance for systematic reviews without meta-analysis, we searched Embase, Scopus, and PubMed from inception to July 2026 for double-arm randomized trials of pirtobrutinib in CLL/SLL. We extracted safety and efficacy data from the trials and synthesized it narratively. Results: Of 500 identified records, 3 trials met eligibility criteria. In relapsed/refractory patients previously treated with a covalent BTK inhibitor (CLL-321), pirtobrutinib reduced progression or death by 46% versus investigator’s-choice therapy (HR: 0.54). In treatment-naive patients (CLL-313), pirtobrutinib reduced risk by 80% versus bendamustine-rituximab (HR: 0.20). In CLL-314, pirtobrutinib was noninferior to ibrutinib on objective response rate (87.0% vs. 78.5%) with a favorable early progression-free survival trend (HR: 0.57). Overall survival data remained inconclusive across trials, complicated by substantial crossover. Importantly, pirtobrutinib consistently showed lower rates of grade ≥3 adverse events, discontinuations, and cardiovascular toxicity, including markedly reduced atrial fibrillation versus ibrutinib. Conclusions: Pirtobrutinib demonstrates consistent efficacy and a favorable safety profile across relapsed/refractory and treatment-naive CLL/SLL settings, with the strongest evidence in patients who progressed on covalent BTK inhibitors. However, longer follow-up and head-to-head comparisons with other covalent inhibitors are warranted to establish its frontline role in this population.

20 October 2026 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
FFFaiza Fatima
Faiza Fatima
MJMuhammad A. Javed
Muhammad A. Javed
AMAeliya Mirza
Aeliya Mirza
SAShahzaib Ahmad
Shahzaib Ahmad
ZSZara Shahzad
Zara Shahzad
AMAli Murad
Ali Murad
Objectives: Kirsten rat sarcoma viral oncogene homolog mutations drive over 90% of pancreatic ductal adenocarcinoma (PDAC). Direct RAS inhibitors have shown early activity, but the only prior meta-analysis pooled early-phase monotherapy cohorts and predates the first phase 3 randomized trial and newer combination regimens. We estimated the objective response rate (ORR), disease control rate (DCR), and safety of Kirsten rat sarcoma viral oncogene homolog-targeted therapy in locally advanced or metastatic PDAC. Methods: PubMed/MEDLINE, Embase, and SCOPUS were searched from inception through July 2026. Single-arm proportions were pooled using a random-effects generalized linear mixed model; RASolute 302 was analyzed separately. Prespecified subgroups stratified ORR by mechanistic class and line of therapy. Results: A total of 1008 patients from 16 cohorts across 7 trials were included; 15 single-arm cohorts (507 patients) contributed to pooled estimates. Pooled ORR was 38.9% (95% CI: 29.9%-48.8%; I 2 =75.7%) and varied significantly by mechanism ( P <0.0001): combination regimens showed the highest activity (60.5%), followed by G12D-selective (31.0%), pan-RAS(ON) (26.6%), and G12C-selective monotherapy (25.4%). Response declined with successive lines of therapy ( P =0.0102), from 72.5% in treatment-naive patients to 32.5% after ≥3 prior lines. Pooled DCR was 87.6% (95% CI: 82.8%-91.2%). Grade ≥3 treatment-related adverse events occurred in 47.3%. In RASolute 302, daraxonrasib nearly doubled median overall survival versus chemotherapy (13.2 vs. 6.6 mo). Conclusions: Kirsten rat sarcoma viral oncogene homolog-directed therapy produces meaningful antitumor activity in previously treated PDAC, greatest for combination regimens and earlier treatment; the evidence remains heterogeneous and largely early-phase, and randomized trials are needed before routine adoption.